Physician profile
Gansevoort H Dunnington
NPI 1740200880
$440,268.62
in general payments reported to CMS, 2019-2025
5 companies · $440K in 2025
The $440K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.20 · 2020: $103 · 2025: $440K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $440K · Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $439,594.47 |
| Food and Beverage | $537.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulse Biosciences, INC. | $440,131.71 | 2025 | Cellfx |
| Inari Medical, INC. | $86.83 | 2020 | |
| Biotronik INC. | $22.43 | 2019 | |
| Kls-Martin L.P. | $15.88 | 2020 | |
| Irhythm Technologies, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gansevoort Dunnington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.